The slippery slope of the human gene editing debate
By John Evans,
Oxford University Press Blog
| 09. 22. 2020
The ethical debate about what is now called “human gene editing” (HGE) began sixty years ago. At the time, eugenicist scientists wanted to use new knowledge about the structure of DNA to modify humans—to perfect the human species by making us more healthy, musical, intelligent, and generally virtuous. A consensus later formed that gene editing on individuals to remove disease is acceptable, but nobody should try to change the human species. This is known as the somatic (individual) vs. germline (species) distinction, and it served as a moral limit on HGE for 50 years. A few years ago the news broke that a Chinese scientist had facilitated the creation of children who have been genetically modified so their descendants would also be modified—germline HGE. The germline limit now seems to be gone. Are there any limits left?
The HGE debate, like many bioethical debates, is set up like a slippery slope. At the top is an act universally considered morally virtuous (point A). Stepping on the slope at the top makes the act a little bit further down the slope...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Briana Contreras, Managed Healthcare Executive | 06.17.2025